- Bone Metastases in Follicular Carcinoma of Thyroid. [Journal Article]
- IJIndian J Otolaryngol Head Neck Surg 2018; 70(1):10-14
- Though the association between follicular carcinoma and bone metastasis is well established, the site-wise distribution is not known. One hundred seventy-three patients of follicular carcinoma presen...
Though the association between follicular carcinoma and bone metastasis is well established, the site-wise distribution is not known. One hundred seventy-three patients of follicular carcinoma presenting between 2003 and 2011 were selected from 1093 patients of follicular lesions presenting at a single institution. Of these, 59 (34%) with bone metastasis were included in the study. Fifty of the 59 patients (84.7%) had metastasis at presentation, while 9 developed bone metastasis during follow-up. Sixty-one percent had solitary metastasis, 15 (25.4%) had multiple bone involvement, while 8 patients (13.6%) had synchronous lung metastasis. Overall, the spine was the commonest site of bone metastases, seen in 20 patients (33.9%), followed by the pelvis, skull, long bones and sternum. Bone metastasis is a known phenomenon in follicular carcinoma. The spine is the commonest site followed by the pelvis.
- The relationship between local recurrences and distant metastases in prostate cancer: can11C-choline PET/CT contribute to understand the link? [Journal Article]
- EJEur J Nucl Med Mol Imaging 2018 Feb 16
- CONCLUSIONS: We found no differences in the rates of lymph node and bone metastases between patients with and without LR. An inverse time-dependent trend was observed in the frequency of LR on one side and of lymph node and bone metastases on the other side. These findings were discussed in relation to previous theories linking LR to distant metastases and our study design.
- EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. [Journal Article]
- EJEur J Nucl Med Mol Imaging 2018 Feb 16
- The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accu...
The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 (89Sr), samarium-153 (153Sm) lexidronam (153Sm-EDTMP), and phosphorus-32 (32P) sodium phosphate; (b) performing the treatments; and
- AR Expression in Breast Cancer CTCs Associates with Bone Metastases. [Journal Article]
- MCMol Cancer Res 2018 Feb 16
- CONCLUSIONS: This study highlights a role for the androgen receptor in breast cancer bone metastasis, and suggests that therapeutic targeting of the androgen receptor may benefit patients with metastatic breast cancer.
- Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature. [Journal Article]
- MCMol Cancer Res 2018 Feb 16
- The trend towards precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration resistant prostate cancer (mCRPC). However, cu...
The trend towards precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration resistant prostate cancer (mCRPC). However, current approaches for molecular characterization are primarily tissue based, necessitating serial biopsies to understand changes over time and are limited by the challenges inherent to extracting genomic material from predominantly bone metastases. Therefore, a circulating tumor cell (CTC)-based assay was developed to determine gene expression across a panel of clinically relevant and potentially actionable prostate cancer related genes. CTCs were isolated from the whole blood of mCRPC patients (n=41) and multiplex qPCR was performed to evaluate expression prostate cancer related target genes (n=78). A large fraction of patients (27/41, 66%) had detectable CTCs. Increased androgen receptor (AR) expression (70% of samples) and evidence of Wnt signaling (67% of samples) was observed. The TMPRSS2:ERG fusion was expressed in 41% of samples and the aggressive prostate cancer associated long non-coding RNA SChLAP1 was upregulated in 70%. WNT5a (HR 3.62, 95% CI 1.63 - 8.05, p=0.002), AURKA (HR 5.56, 95% CI 1.79 - 17.20, p=0.003), and BMP7 (HR 3.86, 95% CI 1.60 - 9.32, p=0.003) were independently predictive of overall survival (FDR<10%) after adjusting for a panel of previously established prognostic variables in mCRPC (Halabi nomogram). A model including Halabi, WNT5a, and AURKA expression, termed the miCTC score, outperformed the Halabi nomogram alone (AUC=0.89 vs. AUC=0.70). Understanding the molecular landscape of CTCs has utility in predicting clinical outcomes in patients with aggressive prostate cancer and provides an additional tool in the arsenal of precision-based therapeutic approaches in oncology.
- Skull metastasis revealing a renal tumor: A case report and review of the literature. [Journal Article]
- IJInt J Surg Case Rep 2018 Feb 10; 43:56-60
- CONCLUSIONS: Although metastases to the head and neck occur infrequently, they should be considered when evaluating any unusual subcutaneous mass in the head and neck. RCC should not be discounted when sites as unlikely as the calvaria are evaluated. Treatment of metastatic renal cell carcinoma is complex, and the optimal regimen for achieving a lasting response without severe toxicity has not yet been defined.
- Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. [Journal Article]
- JOJAMA Oncol 2018 Feb 15
- CONCLUSIONS: Among patients with localized high-risk soft tissue sarcoma the addition of regional hyperthermia to neoadjuvant chemotherapy resulted in increased survival, as well as local progression-free survival. For patients who are candidates for neoadjuvant treatment, adding regional hyperthermia may be warranted.
- Pleomorphic liposarcoma of bone: a rare primary malignant bone tumour. [Journal Article]
- CSClin Sarcoma Res 2018; 8:2
- CONCLUSIONS: Pleomorphic liposarcoma can present as a sclerotic primary malignant bone tumour; markers of adipose differentiation are useful in histological diagnosis and neoadjuvant MAP chemotherapy results in significant tumor necrosis.
- Prospective comparative study of18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. [Journal Article]
- AOActa Oncol 2018 Feb 15; :1-7
- CONCLUSIONS: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD; however, BS seemingly detects PD by the PCWG-2 criteria earlier than NaF-PET, which might be explained by the fact that NaF-PET is more sensitive at the baseline scan.
New Search Next
- Widespread finger skin metastases of melanoma. [Journal Article]
- CCClin Case Rep 2018; 6(2):448-449
- Metastatic melanoma is a fatal disease with a rapid systemic dissemination. Almost every organ might be affected, but lungs, liver, bone, brain, and skin are the most frequently involved sites. Intra...
Metastatic melanoma is a fatal disease with a rapid systemic dissemination. Almost every organ might be affected, but lungs, liver, bone, brain, and skin are the most frequently involved sites. Intravascular microtumoral embolism is believed to account for the distant cutaneous metastases that might be the first manifestation of disease progression in most of the cases.